Upcoming event
40th Annual EAU Congress
Back

Tag: ASCO21

Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis

ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC)

The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES

PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center

Diagnostic performance of Gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging in early-relapsed prostate cancer: Phase 3, prospective, multicenter study (IAEA-PSMA study)

Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes

ACIS study

VISION study

PEACE-1 trial